Breaking News, Collaborations & Alliances

Tonix Vaccine Selected for Inclusion in NIAID COVID Vax Trials

NIAID will cover the full cost of the clinical trial and Tonix will be responsible for providing clinical trial materials for TNX-1800.

Tonix Pharmaceuticals, Inc., a biopharmaceutical company, reported that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), will conduct a Phase 1 clinical trial with the company’s TNX-1800 (recombinant horsepox virus, live vaccine) vaccine candidate in development for COVID-19. Tonix is developing a novel vaccine platform initially targeting COVID-19, smallpox and mpox (monkeypox). The intent is to provide durable protec...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters